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Background
It is now accepted that breast cancer can be divided into 
at least ﬁ ve subtypes based solely on transcription 
proﬁ ling. Although this proﬁ ling has been an extremely 
useful tool for identifying biological diﬀ erences and 
similarities between breast cancers, it speaks little to the 
driver events that lead to each of the subtypes. Identi-
ﬁ cation of these driver events has been the focus of many 
large-scale projects, including Th e Cancer Genome Atlas.
Deﬁ ning the genomic landscape of cancers has 
accelerated dramatically with advances in sequencing 
technologies. However, a single snapshot of acquired 
genomic changes is inherently limited in deﬁ ning 
processes important to the initiation, development, and 
progression of a particular tumor. No genome is static, 
especially a cancer genome with compromised DNA 
repair capabilities. Point mutations, copy number changes, 
and structural changes can all be critical events driving 
tumor evolution or can be bystander passenger events 
not contributing to the disease. Further complicating the 
picture, the vast genetic heterogeneity between tumors 
within a given subtype is made worse by the extensive 
heterogeneity within each tumor. Understanding the 
somatic events driving the evolution of breast cancers 
will undoubtedly lead to novel therapeutic targets. 
However, as the ﬁ ve articles in the June release of Nature
show [1-5], novel driver events are present in increasingly 
rare groups of individuals, making their identiﬁ cation 
extremely diﬃ  cult and raising serious challenges to drug 
development and clinical trials design.
Articles
Th e authors proﬁ led either unselected [3-5], triple-
negative [1], or estrogen-receptor positive breast cancer 
[2] utilizing various technical approaches, including 
whole-genome sequencing, whole-exome sequencing, 
copy number proﬁ ling, and transcriptome analysis. 
Curtis and colleagues [5] integrate expression and copy 
number to identify ten subtypes of breast cancers and 
reveal aberration hotspots responsible for these groups. 
Th ese hotspots contain known (ERBB2, MYC) and 
candidate driver loci that can impact patient prognosis. 
Stephens and colleagues [4] combined copy-number and 
sequencing to identify a number of novel driver genes 
(MAP3K1, MAP2K4, MAP3K13, and AKT2), albeit each 
at relatively low frequency. Together, however, these 
muta tions all impact JUN signaling activation and en-
compass approximately 50% of all breast tumors, thus 
identifying a major recurrent pathway alteration in breast 
cancer. Banerji and colleagues [3] similarly utilize 
sequen cing to identify driver mutations and copy number 
events, including collaborating events in CBFB and 
RUNX1. In triple-negative breast cancers (TNBCs) a 
recurrent MAGI3-AKT3 fusion was identiﬁ ed leading to 
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constitutive activation of AKT signaling. Interestingly, 
somatic activating mutations in ERBB2 without ampliﬁ -
cation were observed. Shah and colleagues [1] also report 
somatic mutation of ERBB2 in TNBC, revealing that this 
pathway may be critical in the absence of ampliﬁ cation. 
Following their genome/exome-wide sequencing eﬀ orts, 
somatic mutations were re-sequenced at 20,000× to 
determine clonal frequencies and distributions of these 
mutations. Th is revealed a wide spectrum of clonal 
frequencies and total number of clonal populations. 
Within TNBCs, basal cancers tended to have more clonal 
frequency groups compared to non-basal cancers. 
Further, this reveals that extensive clonal evolution has 
already occurred in treatment-naïve tumors. Finally, Ellis 
and colleagues [2] focus on estrogen receptor-positive 
breast tumors to identify mutations that result in resis-
tance to neoadjuvant aromatase inhibitor therapy. Resis-
tant tumors tended to have increased mutation rates, 
indicating that genetic heterogeneity may negatively 
impact treatment response. TP53 mutations were also 
found at a higher rate in the poorer prognosis luminal B 
subtype while MAP3K1 mutations were found more in 
luminal A tumors. Further, GATA3 mutations tended to 
correlate with strong response to aromatase inhibitors.
Viewpoint
Together these studies eﬀ ectively integrate orthogonal 
datasets to understand breast cancer drivers. One of the 
major themes throughout the studies is the negative 
impact of genetic heterogeneity on the tumor prognosis 
and/or response to therapy. Intuitively this makes sense; 
a genetically diverse tumor is evolutionarily strong and 
can quickly adapt to changing physiological conditions 
and/or targeted therapies. Unfortunately, this makes 
application of these ﬁ ndings to the clinic extremely 
diﬃ  cult. However, it is encouraging that rare mutations 
were reproduced in independent studies, including 
GATA3 mutations in estrogen receptor-positive disease 
[2-4], ERBB2 mutations in TNBC [1,3], and TBX3 [2,4], 
CBFB, and/or RUNX1 mutations [2,3]. Th e combination 
of rare or unique somatic events into pathways has 
identi ﬁ ed, and will likely continue to identify, drivers of 
breast cancer. It is important to note that the analyses 
under taken on these multiple and massive datasets are 
only the tip of the iceberg, but serve as an excellent 
resource for many additional scientiﬁ c questions. Th ese 
include, but are not limited to: 1)  what is the level of 
mutational heterogeneity within primary and metastatic 
tumors and is this heterogeneity critical to patient 
prognosis and response to therapy; 2)  how do genetic 
aberrations alter and/or co-operate with epigenomic and 
proteomic changes to drive tumor progression; and 
3)  what are the minimal number of events needed to 
reliably identify major prognostic subtypes in breast 
cancer. Future studies examining how somatic events 
evolve during therapy and progression will likely identify 
more clinically actionable drivers.
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